WEBINAR: Leveraging Predictive Dosing to Reduce Clinical Trial Risk

Register Now
Computational diagnosis

A recent study conducted by AiCure and Tufts’ Center for Drug Development found that 48% of study volunteers had at least one intentionally non-adherent dose, and volunteers who deliberately chose not to take their first dose were 5 times more likely to continue to be non-adherent.

Join AiCure, in partnership with Xtalks, for a thoughtful discussion exploring how AI and predictive dosing solutions can reduce risk in clinical trials, helping to eliminate intentional non-adherence early, to reduce timelines, lower costs, and retain trial data integrity.


  • Rich Christie MD PhD, Chief Development Officer at AiCure
  • Ken Getz MBA, Director & Professor at Tufts Center for the Study of Drug Development, Tufts University School of Medicine
  • Dooti Roy PhD, Principal Methodology Statistician at Boehringer Ingelheim
  • Marlen Rattiner, VP, Product Management at AiCure (moderator)